Glipizide-d11 – 500 µg

Brand:
Cayman
CAS:
1189426-07-0
Storage:
-20
UN-No:
Non-Hazardous - /

Glipizide-d11 is intended for use as an internal standard for the quantification of glipizide (Item No. 11579) by GC- or LC-MS. Glipizide is a hypoglycemic agent.{46791} It inhibits ATP-sensitive potassium (KATP) channels in primary mouse pancreatic β cells (IC50 = 6.4 nM). Glipizide induces insulin release from isolated rat pancreatic tissue with an EC50 value of 40 nM.{46792} Dietary administration of glipizide (5 mg/kg per day for 10 days) increases the number of insulin receptors on isolated and purified mouse liver plasma membranes.{46793} It reduces plasma glucose and triglyceride, but not total cholesterol, levels and increases plasma insulin levels in a rat model of diabetes induced by a high-fat diet and streptozotocin (STZ; Item No. 13104) when administered orally at a dose of 5 mg/kg.{46794} Formulations containing glipizide have been used in the treatment of type 2 diabetes.  

 

Available on backorder

SKU: 30074 - 500 µg Category:

Description

An internal standard for the quantification of glipizide by GC- or LC-MS


Formal name: N-[2-[4-[[[(cyclohexyl-1,2,2,3,3,4,4,5,5,6,6-d11-amino)carbonyl]amino]sulfonyl]phenyl]ethyl]-5-methyl-2-pyrazinecarboxamide

Synonyms:  CP 28720|K 4024|TK 1320

Molecular weight: 456.6

CAS: 1189426-07-0

Purity: ≥98% deuterated forms (d1-d11)

Formulation: A solid